Pdt Partners, LLC Regenxbio Inc. Transaction History

Pdt Partners, LLC

$1.01 Billion
Q1 2024

A detailed history of Pdt Partners, LLC transactions in Regenxbio Inc. stock. As of the latest transaction made, Pdt Partners, LLC holds 34,387 shares of RGNX stock, worth $402,327. This represents 0.07% of its overall portfolio holdings.

Number of Shares

34,387

Holding current value

$402,327

% of portfolio

0.07%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$12.17 - $24.61 $418,489 - $846,264	34,387 New	34,387 $724,000
Q3 2022 Nov 14, 2022	SELL	$22.29 - $35.04 $144,416 - $227,024	-6,479 Reduced 42.11%	8,906 $235,000
Q2 2022 Aug 15, 2022	BUY	$19.35 - $35.04 $26,316 - $47,654	1,360 Added 9.7%	15,385 $380,000
Q1 2022 May 16, 2022	BUY	$24.62 - $34.31 $74,475 - $103,787	3,025 Added 27.5%	14,025 $465,000
Q4 2021 Feb 14, 2022	BUY	$30.19 - $40.28 $332,090 - $443,080	11,000 New	11,000 $360,000

Q3 2021 Nov 15, 2021	SELL	$29.09 - $45.68 $1.46 Million - $2.3 Million	-50,331 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$32.46 - $40.48 $442,949 - $552,390	-13,646 Reduced 21.33%	50,331 $1.96 Million
Q1 2021 May 17, 2021	BUY	$33.61 - $49.95 $638,153 - $948,400	18,987 Added 42.2%	63,977 $2.18 Million
Q4 2020 Feb 16, 2021	SELL	$26.52 - $49.35 $486,191 - $904,733	-18,333 Reduced 28.95%	44,990 $2.04 Million
Q3 2020 Nov 16, 2020	BUY	$27.01 - $40.26 $1.13 Million - $1.68 Million	41,657 Added 192.27%	63,323 $1.74 Million
Q2 2020 Aug 14, 2020	BUY	$27.75 - $43.44 $601,231 - $941,171	21,666 New	21,666 $798,000
Q3 2018 Nov 14, 2018	SELL	$65.0 - $82.15 $2.79 Million - $3.53 Million	-42,946 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$27.2 - $74.35 $356,320 - $973,984	13,100 Added 43.89%	42,946 $3.08 Million
Q1 2018 May 15, 2018	BUY	$24.05 - $37.5 $717,796 - $1.12 Million	29,846 New	29,846 $891,000

Others Institutions Holding RGNX

# of Institutions

192

Shares Held

42.1M

Call Options Held

80.6K

Put Options Held

55.2K

View Full List

About REGENXBIO Inc.

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $506M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

More about RGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.

Account